Table 1.
Clinical patients’ characteristics in DOCC registry. Clinical characteristics of patients with the DOCC registry with fatal outcome of COVID-19 (n = 230) and resolved COVID-19 (n = 600) in the total group of patients (n = 830).
| Variable | Resolved (n = 600) |
Fatal (n = 230)d | Total group (n = 830)d | |
|---|---|---|---|---|
| No hospital admission indicated (n = 233)d | Admitted to hospital (n = 367)d | |||
| Sex — n (%) | ||||
| Male | 87 (37.3) | 206 (56.1) | 149 (64.8) | 442 (53.3) |
| Female | 146 (62.7) | 161 (43.9) | 81 (35.2) | 388 (46.7) |
| Age | ||||
| Median age in years (interquartile range) | 60 (49.5–68) | 69 (61–76) | 75 (68–81) | 69 (60–76) |
| <65 years — n (%) | 153 (65.7) | 127 (34.6) | 29 (12.6) | 309 (37.2) |
| ≥65 years < 75 years — n (%) | 48 (20.6) | 122 (33.2) | 85 (37.0) | 255 (30.7) |
| ≥75 years — n (%) | 32 (13.7) | 118 (32.2) | 116 (50.4) | 266 (32.0) |
| Smoking — n (%) | ||||
| All smokers | 84 (36.0) | 190 (51.8) | 127 (55.2) | 401 (48.3) |
| Current smoker | 11 (4.7) | 16 (4.4) | 17 (7.4) | 44 (5.3) |
| History of smoking | 73 (31.3) | 174 (47.4) | 110 (47.8) | 357 (43.0) |
| Unknown | 36 (15.5) | 49 (13.4) | 38 (16.5) | 123 (14.8) |
| Presence of comorbidities - n (%) | ||||
| Cardiovascular disease | 75 (32.2) | 207 (56.4) | 156 (67.8) | 438 (52.8) |
| BMIa≥ 30 | 54 (23.2) | 75 (20.4) | 37 (16.1) | 166 (20.0) |
| COPDb | 11 (4.7) | 48 (13.1) | 37 (16.1) | 96 (11.6) |
| Diabetes mellitus | 27 (11.6) | 72 (19.6) | 54 (23.5) | 153 (18.4) |
| Autoimmune disease | 14 (6.0) | 21 (5.7) | 16 (7.0) | 51 (6.1) |
| Prior/other malignancy | 22 (9.4) | 64 (17.4) | 73 (31.7) | 159 (19.2) |
| Use of steroids at COVID-19 diagnosis | 36 (15.5) | 80 (21.8) | 68 (29.6) | 184 (22.2) |
| As part of cancer treatmente | 31 (86.1) | 43 (53.8) | 38 (55.9) | 112 (60.9) |
| Use >1 weeke | 13 (36.1) | 33 (41.3) | 31 (45.6) | 77 (41.8) |
| Cancer type — n (%) | ||||
| Breast cancer | 61 (26.2) | 35 (9.5) | 21 (9.1) | 117 (14.1) |
| Non small-cell lung cancer | 14 (6.0) | 52 (14.2) | 41 (17.8) | 107 (12.9) |
| Colorectal cancer | 23 (9.9) | 39 (10.6) | 16 (7.0) | 78 (9.4) |
| Non-Hodgkin lymphoma | 13 (5.6) | 35 (9.5) | 21 (9.1) | 69 (8.3) |
| Prostate cancer | 12 (5.2) | 31 (8.4) | 25 (10.9) | 68 (8.2) |
| Cancer subgroups — n (%) | ||||
| Haematological malignancies | 31 (13.3) | 109 (29.7) | 79 (34.3) | 219 (26.4) |
| Lung cancer | 16 (6.9) | 57 (15.5) | 44 (19.1) | 117 (14.1) |
| Neuro-oncological malignancies | 9 (3.9) | 12 (3.3) | 4 (1.7) | 25 (3.0) |
| Other solid tumours | 177 (75.9) | 189 (51.5) | 103 (44.8) | 469 (56.5) |
| Last cancer treatment — n (%) | ||||
| Surgery | 33 (14.2) | 34 (9.3) | 17 (7.4) | 84 (10.1) |
| Radiotherapy | 29 (12.4) | 65 (17.7) | 28 (12.2) | 122 (14.7) |
| Thoracic radiotherapy | 17 (7.3) | 28 (7.6) | 21 (9.1) | 66 (8.0) |
| Chemotherapy | 93 (39.9) | 153 (41.7) | 93 (40.4) | 339 (40.8) |
| Immunotherapy | 46 (19.7) | 58 (15.8) | 36 (15.7) | 140 (16.9) |
| Targeted therapy | 41 (17.6) | 60 (16.3) | 30 (13.0) | 131 (15.8) |
| Hormonal therapy | 37 (15.9) | 32 (8.7) | 27 (11.7) | 96 (11.6) |
| Disease stage solid tumours — n (%) | ||||
| Metastatic | 90 (38.6) | 120 (32.7) | 86 (37.4) | 288 (34.7) |
| Intention most recent cancer treatment given — n (%) | ||||
| Curative | 117 (50.2) | 147 (40.1) | 81 (35.2) | 345 (41.6) |
| Non-curative | 114 (48.9) | 202 (55.0) | 139 (60.4) | 455 (54.8) |
| Unknown | 2 (0.9) | 18 (4.9) | 10 (4.3) | 30 (3.6) |
| Diagnostic confirmation SARS-CoV-2cinfection | ||||
| PCR | 229 (98.3) | 354 (96.5) | 223 (97.0) | 806 (97.1) |
| Serology (presence of antibodies) | 4 (1.7) | 13 (3.5) | 7 (3.0) | 24 (2.9) |
| Treatment restrictions — n (%) | 39 (16.7) | 180 (49.0) | 199 (86.5) | 418 (50.4) |
COVID-19, coronavirus disease 2019; DOCC, Dutch Oncology COVID-19 Consortium; PCR, polymerase chain reaction.
a
BMI, body mass index
b
COPD, chronic obstructive pulmonary disease
c
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
d
Percentage is expressed as total number of patients with particular variable within group of patients with similar outcomes of COVID-19-.
e
Within group of patients with steroids.